Drug intelligence / Profile preview

tl938

Development stage: Phase 2
Lead developer: Teligene
Modality: Small Molecules
Administration: Oral

Overview

TL938 is an oral small molecule HER2 inhibitor being developed by Suzhou Teligene for the treatment of HER2-positive solid tumors, including advanced colorectal cancer. It is currently in clinical trials to evaluate its safety, tolerability, pharmacokinetics, and efficacy both as a monotherapy and in combination with trastuzumab. The drug is designed to cross the blood-brain barrier and has been studied for its potential activity against brain metastases[1][2][3].

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on tl938.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tl938.

Explore the full profile